Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Pfizer Zoloft And Xanax XR Provide “Complete Solution” For Anxiety

  • News

Executive Summary

Pfizer's Zoloft and recently launched Xanax XR provide the "complete solution for patients across a number of anxiety positions," Pfizer President Global Pharmaceuticals Karen Katen said during an analyst meeting in New York June 17

You may also be interested in...



Sepracor Estorra NDA Filing Planned By Mid-Feb.; Xopenex MDI By Year-End

Sepracor is planning an NDA filing for its sleep disorder drug Estorra by Feb. 15, followed by a submission for its Xopenex metered dose inhaler formulation before year-end

Xanax XR approved

Pharmacia's once-daily formulation of alprazolam, Xanax XR, clears FDA Jan. 17 for treatment of panic disorder. Immediate-release Xanax is generally dosed 3-4 times daily...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Table

View full table

Tags:
Latest Headlines

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The Aspirin Test For AI?

Mary Beth Clarke, CDER Exec Programs Office Director And Generic User Fee Shepherd, Will Retire

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

See All
UsernamePublicRestriction

Register

PS042016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By